Which body parts warrant the biggest biotech venture investments?

John Carroll Dow Jones writer Brian Gormley set out to find out the answer to that question, reviewing the venture data for biotech and med tech in Dow Jones' VentureSource database. FierceBiotech ...

What’s the #1 biotech hub for VCs? (It’s still not Boston)

John Carroll Biotech investing is sizzling right now, and despite all the attention that the Boston hub gets, the Bay Area is still number one. FierceBiotech News

Another Israeli biotech braves choppy IPO waters

John Carroll The latest batch of Israeli biotechs to hit Nasdaq hasn't been doing so well. But that hasn't deterred Foamix Pharmaceuticals from joining the tail end of the big ...

Biotech IPOs sputter amid downsizings, disappointments and white flags

Damian Garde Six biotechs were expected to go public this week, eyeing nearly $ 400 million combined, but that potential has so far amounted to one deeply discounted offering, one ...

Inovio vs. Feuerstein, Round II: Biotech claims PhII success for VGX-3100

John Carroll Shares of Inovio Pharmaceuticals jumped about 20% this morning after the biotech said it had hit the mark on the primary endpoint for its mid-stage study of VGX-3100, an ...

Biotech VCs bet $1.8B in a colossal Q2

Damian Garde Biotechs raked in a whopping $ 1.8 billion in venture cash last quarter, the industry's biggest haul since PricewaterhouseCoopers and the National Venture Capital ...

U.K. pols ready for Pfizer’s return, AZ cozies up to EU academia, Israeli biotech upsizes IPO

Nick Paul Taylor In this week's EuroBiotech Report, no politicians are rushing to Shire's rescue as it attempts to fend off AbbVie, but lawmakers in the United Kingdom are readying ...

Neuropsychiatric biotech raises $20M for PhII program

John Carroll The biotech is also planning to launch studies for SNC-102 in Tourette syndrome and post-traumatic stress syndrome. Accellient seeded Synchroneuron up to its $ 6 million ...

Alkermes sues Boston biotech startup for trademark infringement

Emily Mullin Startup Alkeus is being sued by Irish drugmaker Alkermes for trademark infringement. According to the Boston Business Journal, the 25-year-old Alkermes filed the lawsuit ...

Teva and Active Biotech not giving up on EU-spurned MS treatment

Carly Helfand The EU's Committee for Medicinal Products for Human Use (CHMP) is sticking to its opinion to recommend against approval of Teva and Active Biotech's MS drug Nerventra. ...

VC Lightstone lands $172M with an eye on biotech startups

Damian Garde Lightstone Ventures, the life sciences-focused progeny of two VC stalwarts, has wrapped up a fund of its own, setting out with $ 172 million to back early-stage drug and ...

GSK and Novartis reshape EU biotech, Celgene and Hyperion in Euro deals, U.K. cell therapy grows

Nick Paul Taylor In the latest edition of our weekly EuroBiotech Report, the card shuffling at GlaxoSmithKline and Novartis is raising questions about the future of several companies. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS